Key
achievements
The new Kedrion continues a Journey of Science and Humanity begun decades ago in Italy and the UK.
With new assets and increased capacities, the new Kedrion continues a Journey of Science and Humanity begun decades ago in Italy and in the UK.
During our internationalization journey we have gradually expanded our reach globally to countries such as Canada, the US, and Hungary. Science in the service of Humanity. Humanity informing Science.
A glimpse of a vibrant company
At a glance
5,000+ employees worldwide
37 products
Approved in at least one market
100+ countries distribution
7 production plants in 5 countries
5th largest world player in the sector
Source: Marketing Research Bureau “The Worldwide Plasma Proteins Market 2022” and publicly available information
68 plasma collection centers in the US
5 plasma collection centers in the Czech Republic
According to data updated end of 2023
All our medical and scientific efforts aim to help people facing serious and rare health challenges. As we boost scientific research, we enhance our ability to reach more patients in more places.
Snapshot of a company on the move
With Science and Humanity as its traveling companions, Kedrion is on the move.
Through growth, innovation, and the continuous exchange of skills, Kedrion has remained focused on one primary goal: helping people. 2023 marked a year of new beginnings for Kedrion as it re-committed to leadership in the field of plasma-derived therapies for challenging rare and ultra-rare diseases and conditions, serving patients around the world.
An outstanding year for Kedrion
2023 represented a chapter of extraordinary growth for Kedrion.
We made a strong commitment not only to reach all the operational and financial goals we had set ourselves, but also to complete the integration between Kedrion and BPL. Our commitment is to play a positive and tangible role in the lives of the communities where we are present, with the ambition to contribute to designing a better future together.
Our year in numbers
Revenues
Reported EBITDA
CAPEX Investments
Data on a like-for-like basis calculated pro forma for the entire 2022 financial year
According to data updated end of 2023
Ulrike Becker
Find out what our Chief Financial Officer has to say on this impressive year
Portugal - A new pipeline for plasma
China - An opening to a major market
A re-commitment to stop Rabies
KEDPLASMA - Excellence gets even better
Maximizing our most precious asset, plasma
Ultra-rare disease therapy: relief at last
Our milestones in a nutshell
2023 marked a year of new beginnings for Kedrion as it re-committed to leadership in the field of plasma-derived therapies for challenging rare and ultra-rare diseases and conditions, serving patients around the world. Kedrion demonstrated its expertise and commitment to global health through several key milestones.
Portugal
A new pipeline for plasma
Continuing its commitment to partner with health systems striving for self-sufficiency in plasma-derived therapies, in 2023 Kedrion began processing plasma from Lisbon, Coimbra, and Porto blood centers to provide Portugal with vital medicines.
China
An opening to a major market
China accounts for nearly half the worldwide demand for human Albumin. In a major announcement by the National Institutes for Food and Drug Control a portion of that demand will be satisfied by Albumin produced in our BPL plant in Elstree, UK.
A re-commitment to stop Rabies
Rabies is a deadly infection spread through the saliva of diseased animals. Since 2018, Kedrion has distributed KEDRAB® (Rabies Immune Globulin [Human]) in collaboration with Kamada. In 2023, we reached an agreement to extend our collaboration through 2026.
KEDPLASMA
Excellence gets even better
In 2022, Kedrion's plasma collection subsidiary, KEDPLASMA, gained 29 collection centers in the US coming from BPL Plasma, totaling 68. In 2023, these centers were re- branded and renovated to enhance the donation experience for generous donors.
Maximizing our most precious asset, plasma
Plasma is a valuable resource for deriving therapies for rare conditions. A recent study funded by Kedrion identified a potential therapy for an ultra-rare condition from unused plasma fractionation intermediates, highlighting the importance of maximizing plasma’s potential.
Ultra-rare disease therapy: relief at last
For the approximately 500 sufferers of Congenital Plasminogen Deficiency Type 1 in the US, relief arrived in the form of stabilizing supply of Kedrion’s RYPLAZIM®, the first FDA- approved treatment for this debilitating ultra-rare condition.